Salivary Gland Cancer - Pipeline Review, H2 2016


#873472

104pages

Global Markets Direct

$ 2000

In Stock

Salivary Gland Cancer - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Salivary Gland Cancer Pipeline Review, H2 2016, provides an overview of the Salivary Gland Cancer (Oncology) pipeline landscape.

Salivary gland cancer is a rare form of cancer that begins in the salivary glands. Salivary gland cancer can begin in any of the salivary glands in mouth, neck or throat. Symptoms include a lump or swelling on or near jaw or in neck or mouth, numbness in part of face, difficulty swallowing and trouble opening mouth widely. Risk factors include age and radiation exposure.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Salivary Gland Cancer Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Salivary Gland Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Salivary Gland Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Salivary Gland Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 1, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.Salivary Gland Cancer.

Salivary Gland Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Salivary Gland Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Salivary Gland Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Salivary Gland Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Salivary Gland Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Salivary Gland Cancer (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Salivary Gland Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Salivary Gland Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Salivary Gland Cancer Overview 6
Therapeutics Development 7
Pipeline Products for Salivary Gland Cancer - Overview 7
Pipeline Products for Salivary Gland Cancer - Comparative Analysis 8
Salivary Gland Cancer - Therapeutics under Development by Companies 9
Salivary Gland Cancer - Therapeutics under Investigation by Universities/Institutes 10
Salivary Gland Cancer - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Salivary Gland Cancer - Products under Development by Companies 13
Salivary Gland Cancer - Products under Investigation by Universities/Institutes 14
Salivary Gland Cancer - Companies Involved in Therapeutics Development 15
Bayer AG 15
Ignyta, Inc. 16
Johnson & Johnson 17
Loxo Oncology, Inc. 18
Merck & Co., Inc. 19
Plexxikon Inc. 20
Taiwan Liposome Company, Ltd. 21
Salivary Gland Cancer - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
Cellular Immunotherapy for Oncology - Drug Profile 31
Product Description 31
Mechanism Of Action 31
R&D Progress 31
entrectinib - Drug Profile 33
Product Description 33
Mechanism Of Action 33
R&D Progress 33
LOXO-101 - Drug Profile 39
Product Description 39
Mechanism Of Action 39
R&D Progress 39
pembrolizumab - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
pexidartinib - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
regorafenib - Drug Profile 84
Product Description 84
Mechanism Of Action 84
R&D Progress 84
tipifarnib - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
TLC-388 - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
Vaccine to Target WT1 for Oncology - Drug Profile 100
Product Description 100
Mechanism Of Action 100
R&D Progress 100
Salivary Gland Cancer - Dormant Projects 101
Salivary Gland Cancer - Discontinued Products 102
Appendix 103
Methodology 103
Coverage 103
Secondary Research 103
Primary Research 103
Expert Panel Validation 103
Contact Us 103
Disclaimer 104

List of Tables
Number of Products under Development for Salivary Gland Cancer, H2 2016 7
Number of Products under Development for Salivary Gland Cancer - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Late Stage Development, H2 2016 11
Comparative Analysis by Clinical Stage Development, H2 2016 12
Products under Development by Companies, H2 2016 13
Products under Investigation by Universities/Institutes, H2 2016 14
Salivary Gland Cancer - Pipeline by Bayer AG, H2 2016 15
Salivary Gland Cancer - Pipeline by Ignyta, Inc., H2 2016 16
Salivary Gland Cancer - Pipeline by Johnson & Johnson, H2 2016 17
Salivary Gland Cancer - Pipeline by Loxo Oncology, Inc., H2 2016 18
Salivary Gland Cancer - Pipeline by Merck & Co., Inc., H2 2016 19
Salivary Gland Cancer - Pipeline by Plexxikon Inc., H2 2016 20
Salivary Gland Cancer - Pipeline by Taiwan Liposome Company, Ltd., H2 2016 21
Assessment by Monotherapy Products, H2 2016 22
Number of Products by Stage and Target, H2 2016 24
Number of Products by Stage and Mechanism of Action, H2 2016 26
Number of Products by Stage and Route of Administration, H2 2016 28
Number of Products by Stage and Molecule Type, H2 2016 30
Salivary Gland Cancer - Dormant Projects, H2 2016 101
Salivary Gland Cancer - Discontinued Products, H2 2016 102

List of Figures
Number of Products under Development for Salivary Gland Cancer, H2 2016 7
Number of Products under Development for Salivary Gland Cancer - Comparative Analysis, H2 2016 8
Number of Products under Development by Companies, H2 2016 9
Number of Products under Investigation by Universities/Institutes, H2 2016 10
Comparative Analysis by Clinical Stage Development, H2 2016 12
Assessment by Monotherapy Products, H2 2016 22
Number of Products by Top 10 Targets, H2 2016 23
Number of Products by Stage and Top 10 Targets, H2 2016 23
Number of Products by Top 10 Mechanism of Actions, H2 2016 25
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 25
Number of Products by Routes of Administration, H2 2016 27
Number of Products by Stage and Routes of Administration, H2 2016 27
Number of Products by Molecule Types, H2 2016 29
Number of Products by Stage and Molecule Types, H2 2016 29